PerpEquities

Guardant Health, Inc. (GH) financials

NASDAQ · Healthcare · Medical - Diagnostics & Research · 2,498 employees · CEO Helmy Eltoukhy

Price
$145.83 +0.16%
Market cap
$19.7B
Enterprise value
$20.4B Data as of 2026-11-22
Last report
Q3 '26 filed 2026-11-05
Next report
2027-02-18 EPS est. -$0.75
Revenue (TTM)$1.28B+41.7% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)-39.4%+9.6 pp vs a year agoOperating income -$504M
Net income (TTM)-$485M-21.6% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$232M+11.5% vs a year agoCapex $58.7M
Diluted EPS (TTM)-$3.68-14.6% vs a year agoSum of the last 4 quarters
Net cash-$665M+11.0% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
$19.7B
Updated 2h ago
Revenue
$1.28B
Trailing 12 months
Revenue growth
+39%
FY2026 consensus
Profit margin
-37.9%
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
15.4×
Price / sales, TTM
EV / EBITDA
-46.2×
TTM
Free cash flow
-$232M
Trailing 12 months
Net income
-$485M
Trailing 12 months
Revenue estimate
$1.37B
FY2026 consensus
Earnings
2027-02-18
Revenue est. $371M · Updated 2h ago
Dividend
–
No dividend

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Last report (2026-11-05): revenue beat by 2.9%, EPS beat by 61.3%Revenue $361M vs $351M expected (+2.9%); EPS -$0.29 vs -$0.75 (+61.3%).
  • Revenue growth slowing: 36.1% year on yearQ3 '26 revenue $361M, against an average of 42.6% over the four quarters before.
  • Operating margin -39.4% (TTM), +9.6 pp on a year agoOperating income grew -13.9% while revenue grew 41.7%.
  • Capex 4.6% of revenue (a year ago 4.4%)$58.7M invested in the last 4 quarters (+49.2% on a year earlier). Free cash flow -$232M.
  • Diluted share count up 7.3% in a year134M diluted shares in Q3 '26, 125M a year earlier.
  • Net debt $665MCash + short-term investments $1.03B, debt incl. leases $1.69B; a year ago net debt $746M.

Last quarter: Q3 '26

Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q3 '26Year agoChange
Revenue$361M$265M+36.1%
Gross margin65.4%64.7%+0.7 pp
Operating income-$133M-$99M-34.1%
Operating margin-36.8%-37.3%+0.5 pp
Net income-$124M-$92.7M-34.1%
Diluted EPS-$0.93-$0.74-25.7%
Operating cash flow-$23.7M-$35.4M+33.1%
Capex$13.5M$10.4M+30.2%
Free cash flow-$37.2M-$45.8M+18.7%
R&D$101M$90M+12.1%
Stock-based compensation$62.4M$42.8M+45.8%

Reported vs consensus

2026-11-05
ActualConsensusvs consensus
Revenue$361M$351M+2.9%
EPS (as estimated)-$0.29-$0.75+61.3%

From the report of 2026-11-05 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Revenue by business line

stacked, quarterly
SegmentQ3 '26y/yShare of listedTTMTTM y/y12 quarters
Oncology$231M+25.4%64.1%$845M–
Screening$67.6M+180.4%18.7%$197M–
Biopharma & Data$59M+7.7%16.3%$227M–
Licensing & Other$3.13M+60.2%0.9%$9.51M–

Revenue by region

share of the listed regions
SegmentQ3 '26y/yShare of listedTTMTTM y/y12 quarters
United States$345M+38.5%95.7%$1.21B+42.3%
Non-US$15.6M-0.9%4.3%$67.3M+31.4%

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement
Operating cash flow
-$173M
Capex
-$58.7M
Buybacks
$0
Dividends
$0
Acquisitions
$0
Net debt issued
$396M
Stock-based compensation
$211M
Free cash flow
-$232M
Returned to shareholders / FCF
0.0%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)–––
EV / EBITDA-46.2×––
EV / Sales15.9×12.9×5.8× – 29.5×
Price / FCF-85.0×––
Price / Book-71.0×27.0× 3 of 5 years15.7× – 46.2×
FCF yield-1.2%-7.5%-13.9% – -1.8%
Return on invested capital-32.6%-30.5%-37.8% – -20.3%
Return on equity249.0%-144.2%-1,087.7% – 419.2%

Analysts

Consensus target $203.40 (+39.5%)
range $180.00 – $225.00 · rating Buy

Strong buy0
Buy30
Hold0
Sell1
Strong sell0

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal yearRevenueGrowthEPSGrowthP/E at today's priceAnalysts (EPS)
FY2026$1.37B+39.2%-$3.44-3.6%-42.4×13
FY2027$1.83B+33.9%-$2.27+34.0%-64.2×13
FY2028$2.51B+36.9%-$0.44+80.4%-328.3×11
FY2029$3.2B+27.7%$0.62+239.8%234.8×4
FY2030$3.84B+19.9%$0.69+11.1%211.3×4

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Every reported line

All 245 figures Guardant Health, Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).

Line (SEC label)Latest quarterYear agoy/yLatest FYPrior FYy/y
Accounts Payable, Current$103M$20.1M+408.9%$54.4M$38.6M+41.2%
Accounts Receivable, after Allowance for Credit Loss, Current$187M$116M+61.4%$138M$110M+25.0%
Accretion (Amortization) of Discounts and Premiums, Investments$0$0–$5.88M$6.77M-13.2%
Accrued Employee Benefits, Current$128M$98.2M+29.9%$120M$83.2M+43.8%
Accrued Liabilities, Current$105M$71.7M+46.3%$77.9M$68.3M+14.0%
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment$224M$191M+17.2%$199M$166M+20.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax-$5.13M-$4.26M-20.5%-$4.85M-$5.2M+6.7%
Additional Paid in Capital$3.08B$2.56B+20.3%$2.9B$2.44B+18.7%
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs–––$17.7M––
Advertising Expense–––$24.1M$0–
Amortization of Debt Discount (Premium)-$1.71M-$1.7M-0.8%-$5.93M$0–
Amortization of Debt Issuance Costs$1.18M$768K+54.0%$3.24M$2.58M+25.6%
Amortization of Intangible Assets$300K$400K-25.0%$1.7M$2.2M-22.7%
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount26.8M27.2M-1.8%26.1M19.2M+35.8%
APIC, Share-based Payment Arrangement, Increase for Cost Recognition$62.4M$42.8M+45.8%$166M$140M+18.4%
Asset Impairment Charges–––$0––
Assets$1.89B$1.28B+47.7%$2.01B$1.49B+35.5%
Assets, Current$1.34B$829M+62.1%$1.47B$1.06B+38.9%
Assets, Fair Value Disclosure$1.26B2025-12-31$904M+39.0%$1.26B$904M+39.0%
Business Combination, Contingent Consideration, Liability$34M––$34M$6.05M+462.0%
Capital Expenditures Incurred but Not yet Paid–––$4.11M$3.81M+7.9%
Cash and Cash Equivalents, at Carrying Value$1.03B$580M+77.0%$378M$526M-28.0%
Cash and Cash Equivalents, Fair Value Disclosure$1.03B––$434M$590M-26.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents$1.15B$690M+66.2%$489M$630M-22.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect-$21.7M-$46M+52.7%-$140M-$504M+72.2%
Common Stock, Capital Shares Reserved for Future Issuance28.9M30M-3.6%28.2M27.1M+3.7%
Common Stock, Par or Stated Value Per Share$0.00$0.000.0%$0.00$0.000.0%
Common Stock, Shares Authorized350M350M0.0%350M350M0.0%
Common Stock, Shares, Issued135M126M+6.9%131M124M+5.4%
Common Stock, Shares, Outstanding135M125M+7.8%131M124M+5.4%
Common Stock, Value, Outstanding$1K$1K0.0%$1K$1K0.0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent-$124M-$93.3M-32.9%-$416M-$438M+5.0%
Contract with Customer, Asset, after Allowance for Credit Loss$6.4M$5.1M+25.5%$5.2M$3.4M+52.9%
Contract with Customer, Liability$45.1M$56.4M-20.0%$59.7M$41.6M+43.5%
Contract with Customer, Liability, Current$38.1M$46.9M-18.7%$50.8M$35.5M+43.1%
Contract with Customer, Liability, Noncurrent$7M$9.5M-26.3%$9M$6.1M+47.5%
Contract with Customer, Liability, Revenue Recognized$9.5M$9.2M+3.3%$35.3M2024-12-31$14.5M+143.4%
Contract with Customer, Performance Obligation Satisfied in Previous Period$8.4M$16.8M-50.0%$33.8M$35.3M-4.2%
Convertible Debt, Noncurrent$1.5B$1.11B+34.8%$1.5B$1.14B+31.6%
Cost of Goods and Services Sold$125M$93.6M+33.4%$349M$290M+20.4%
Costs and Expenses$494M$364M+35.6%$1.42B$1.18B+20.0%
Current Foreign Tax Expense (Benefit)–––$352K$871K-59.6%
Current Income Tax Expense (Benefit)–––$442K$997K-55.7%
Current State and Local Tax Expense (Benefit)–––$90K$126K-28.6%
Debt Instrument, Face Amount$1.09B2025-09-30–––––
Debt Securities, Available-for-sale$1.03B––$1.26B$904M+39.0%
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax$0$0–$130K$232K-44.0%
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax$27K$4K+575.0%$40K$0–
Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)$0$0–$0$0–
Debt Securities, Available-for-sale, Amortized Cost$1.03B––$1.26B$904M+39.1%
Debt Securities, Available-for-sale, Current$0$0–$823M$314M+161.9%
Debt Securities, Current$823M2025-12-31$314M+161.9%$823M$314M+161.9%
Debt Securities, Realized Gain (Loss)$0$0–$0$0–
Deferred Foreign Income Tax Expense (Benefit)–––-$1.71M$287K-694.1%
Deferred Income Tax Expense (Benefit)–––-$1.71M$287K-694.1%
Deferred Tax Assets, Goodwill and Intangible Assets$18.2M2025-12-31$14.4M+26.0%$18.2M$14.4M+26.0%
Deferred Tax Assets, Gross$840M2025-12-31$734M+14.4%$840M$734M+14.4%
Deferred Tax Assets, in Process Research and Development$134M2025-12-31$118M+13.6%$134M$118M+13.6%
Deferred Tax Assets, Net of Valuation Allowance$6.19M2025-12-31$760K+714.3%$6.19M$760K+714.3%
Deferred Tax Assets, Operating Loss Carryforwards$491M2025-12-31$423M+16.1%$491M$423M+16.1%

Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-22